Chi-Ping Huang

8PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)PharmacogenomicsEthical use of new technologyMolecular targetsTraditional Chinese medicine and treatments
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 13, 2026
Feasibility and Oncological Outcomes of Segmental Ureteral Resection Versus Radical Nephroureterectomy for High-Risk Ureteral Urothelial Carcinoma.

|May 16, 2023
Mirabegron is better tolerated than solifenacin in Sjogren's syndrome patients with overactive bladder symptoms-A randomized controlled trial.

Hao Xiang Chen, Shih-Hsin Chang, Der-Yuan Chen

|Aug 31, 2022
Robot-assisted anatrophic nephrolithotomy for complete staghorn stone.

Jen-Kai Fang, Po-Jen Hsiao, Hung-Chieh Chiu

|Aug 29, 2022
High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.

Min Tang, Yin Sun, Chi-Ping Huang

|Apr 29, 2022
Effects of Chinese herbal medicine in patients with benign prostatic hyperplasia: A nationwide cohort study in Taiwan.

Shi-Chen Ou, Sheng-Teng Huang, Mei-Chen Lin

|Jun 15, 2021
Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARĪ³/MMP-9 signals.

Gang Deng, Ronghao Wang, Yin Sun

Pageof 2

Frequent Collaborators

3 joint publications

Chawnshang Chang

2 joint publications

Shi-Chen Ou

2 joint publications

Mei-Chen Lin

2 joint publications

Sheng-Teng Huang